United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $238.81, for a total value of $859,716.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $31,045.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
United Therapeutics Stock Performance
Shares of NASDAQ UTHR traded down $1.05 during trading hours on Thursday, reaching $235.95. The stock had a trading volume of 391,825 shares, compared to its average volume of 439,210. United Therapeutics Co. has a twelve month low of $204.44 and a twelve month high of $261.54. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. The business’s fifty day moving average is $233.36 and its two-hundred day moving average is $228.79. The company has a market cap of $11.10 billion, a price-to-earnings ratio of 11.89 and a beta of 0.52.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. During the same period last year, the firm earned $2.67 EPS. The firm’s revenue for the quarter was up 25.1% compared to the same quarter last year. As a group, research analysts expect that United Therapeutics Co. will post 23.45 EPS for the current year.
Institutional Trading of United Therapeutics
Analyst Ratings Changes
A number of research analysts recently commented on the company. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and upped their price objective for the company from $213.00 to $215.00 in a report on Monday, February 12th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. Wedbush reaffirmed an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $294.25.
Get Our Latest Analysis on UTHR
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading
- Five stocks we like better than United Therapeutics
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Hasbro’s Management Made All the Right Calls This Quarter
- What is the FTSE 100 index?
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- How to Invest in Insurance Companies: A Guide
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.